Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.
Boston Scientific Corporation (NYSE:BSX ) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President, Cardiology Conference Call Participants Travis Steed - Bank of America Travis Steed All right. Good morning, everybody.
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The 2025 Q1 earnings cycle is in full swing. And these three companies posted results that had investors pleased.
Raising guidance? In this uncertainty?
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.